ICR welcomes FDA approval of ‘search and destroy’ treatment 25 Mar 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a potent radioactive medicine that searches for tumour cells to deliver a radioactive payload, has been approved by the US Food and Drug Administration (FDA) for treating some advanced prostate cancers. Find out more Show/Hide